Trial Search Results

International Consortium for Multimodality Phenotyping in Adults With Non-compaction

Non-compaction cardiomyopathy (NCCM) is a heterogeneous, poorly understood disorder characterized by a prominent inner layer of loose myocardial tissue, and associated with heart failure, stroke, severe rhythm irregularities and death. For a growing population diagnosed with NCCM there is a need for better risk stratification to appropriately allocate (or safely withhold) these impactful preventive measures. The goal of this international consortium is to improve care of patients with non-compaction cardiomyopathy. We hypothesize that comprehensive analysis of clinical, genetic, structural and functional information will improve risk stratification. In addition, we hypothesize that detailed structural analysis will allow for differentiation of pathological and benign patterns of non-compaction. In a large cohort of adult patients with suspected NCCM we will perform in-depth phenotyping, including clinical information, pedigree data, genetics, echocardiography and MRI, and follow patients for up to 3 years. We will apply machine-learning based analytics to develop predictive models and compare their performance to currently used models and treatment criteria. Secondly, in a subset of patients we will perform high-resolution cardiac CT for detailed structural characterization of the myocardial wall. We will investigate associations between myocardial structure and regional contractile function, as assessed by echo and MRI. The aim of this proposal is to identify a structural signature associated with pathological non-compaction and improve developed risk prediction models. Discovery of pathological structural signatures through innovative imaging techniques, in relation to myocardial contractility, will advance our understanding of NCCM.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Seoul National University Hospital

Stanford Investigator(s):


  • Diagnostic Test: Echocardiography
  • Diagnostic Test: Magnetic resonance imaging (MRI)
  • Diagnostic Test: Computed tomography (CT)


Inclusion Criteria:

   - ≥18 years old

   - Hypertrabeculation of the left ventricle fulfilling the echo-based Jenni criteria of

   - Clinical cardiac MRI examination performed or planned

Exclusion Criteria (general cohort):

   - Complex congenital disease (including transposition great arteries, tetralogy of
   Fallot, tricuspid atresia, truncus arteriosis, single ventricle, hypoplastic left
   heart, pulmonary atresia, double-outlet RV), neuromuscular disorders or isolated RV

   - Inability to provide informed consent

   - Contra-indications to MRI, which apply if the clinical cardiac MRI has not yet been
   performed at the time of study enrollment: permanent pacemakers/ICDs, MRI contrast
   medium allergy, significant arrhythmia with highly irregular RR intervals, severe
   dyspnea with inability to lay flat/breath hold, inability to communicate with the MRI
   technician or follow commands for any reason (psychosis, agitation, etc.), other
   site-specific contra-indications to clinical MRI of the heart.

Exclusion Criteria (cardiac CT examination):

   - Age <21 years

   - Decompensated heart failure, or otherwise clinically unstable

   - BMI>40 kg/m2

   - Pregnancy (or cannot be ruled out)

   - Known iodine contrast medium allergy

   - Kidney dysfunction: eGFR<45 ml/min

   - Thyroid disease: toxic multinodular goiter, Graves' disease, Hashimoto's thyroiditis

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Koen Nieman, MD, PhD
Not Recruiting